Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −104 vs. previous quarter
- 6
- 13F valueReported value at the end of Q2 2026
- $29.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SGMOQ, Q2 2026
No superinvestor reported holding SGMOQ at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Sangamo Therapeutics, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 (view filing)4:07 PM ET | Apr 22 | 1 day | Davis Gregory DHead of Research & Technology | SSale | −69.8K | $0.2534 | −$17.7K | −37.7%115.3K after | |
| Apr 23, 2026 (view filing)4:05 PM ET | Apr 21 | 2 days | Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | SSale | −345.9K | $0.2578 | −$89.2K | −51.0%332.8K after | |
| Sep 28, 2023 (view filing)5:30 PM ET | Sep 26 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −6.00M | $0.50 | −$3.00M | −25.4%17.7M after | |
| Aug 31, 2022 (view filing)7:03 PM ET | Aug 29-30 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −500.0K | $5.31 | −$2.66M | −2.1%23.7M after | 2 lots |
| Jun 6, 2022 (view filing) | Jun 3 | 3 days | Markels JohnDirector | PPurchase | +6.78K | $3.69 | +$25.0K | +26.4%32.5K after | |
| Jun 3, 2022 (view filing) | Jun 1 | 2 days | Parker H StewartDirector | PPurchase | +5.00K | $3.60 | +$18.0K | +11.4%48.7K after | |
| Dec 30, 2021 (view filing)5:12 PM ET | Dec 28 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −2.76K | $8.51 | −$23.5K | 0.0%24.2M after | |
| Dec 28, 2021 (view filing)8:11 AM ET | Dec 23-27 | 5 days | Biogen Inc. and 1 other10% Owner | SSale | −81.8K | $8.55 | −$699.7K | −0.3%24.2M after | 2 lots |
| Dec 10, 2021 (view filing)4:08 PM ET | Dec 9 | 1 day | Biogen Inc. and 1 other10% Owner | SSale | −23.7K | $8.56 | −$202.5K | −0.1%24.2M after | |
| Dec 9, 2021 (view filing)4:08 PM ET | Dec 7-8 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −128.0K | $8.59 | −$1.10M | −0.5%24.3M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Sangamo Therapeutics, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nomura Asset Management International Inc. | 400,000 | $22.0K | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 76,500 | $4.13K | 0.00% | +76,500 | New |
| Axiom Investment Management LLC | 25,375 | $1.37K | 0.00% | 00.0% | Unchanged |
| Flow Traders U.S. LLC | 21,532 | $1.00K | 0.00% | +34+0.2% | Added |
| Heritage Investment Group, Inc. | 10,000 | $539 | 0.00% | +10,000 | New |
| Barclays PLC | 1 | $0 | 0.00% | 00.0% | Unchanged |